Dossier - 18/10/2010 New machines for the life sciences Hardware and software applications have become an integral part of the everyday life of life sciences researchers, developers and service providers. It is impossible to imagine life science applications without effective hardware and software applications – from computer-assisted drug screening to the automatic production of biosensors for rapid, mobile, purse-size bacterial test devices. Trends such as automation and miniaturisation lead to ever…https://www.gesundheitsindustrie-bw.de/en/article/dossier/new-machines-for-the-life-sciences
Dossier - 22/08/2011 Stress and molecular defence mechanisms Organisms can experience stress from exposure to bacteria and pathogenic fungi; in fact, stress can arise from exposure to any type of environmental influence. As they have evolved, biological cells have developed numerous molecular mechanisms that enable them to survive even in inhospitable conditions. What kind of effects do abiotic stress factors have on plants and human beings? How do cells protect themselves? Are researchers able to increase…https://www.gesundheitsindustrie-bw.de/en/article/dossier/stress-and-molecular-defence-mechanisms
Article - 21/03/2011 Immunotherapy: the rocky road to clinical application Hans-Georg Rammensee has one major goal: he wants to contribute to the successful application of immunotherapy in clinical settings and is convinced that this will only be possible once individualised immunotherapies are used. Individualised immunotherapy refers to the induction of a specific immune response against specific tumour-associated antigens. Rammensee has made major progress in this area and is now focused on overcoming the obstacles…https://www.gesundheitsindustrie-bw.de/en/article/news/immunotherapy-the-rocky-road-to-clinical-application
Guest article - 10/11/2014 Six Months Research in an Incredible City at the other Side of the World The fellowship program “Research stay for application-oriented bioscientists and biotechnologists in Shanghai and Jiangsu/China” funded by the Baden-Württemberg Ministry of Science, Research and the Arts enabled Sonja Blasche to spend six months at the Minhang Campus of the Jiao Tong University in Shanghai. During this time she worked in the laboratory of Professor Zhao Liping, an internationally known expert on microbial communities and the…https://www.gesundheitsindustrie-bw.de/en/article/news/six-months-research-in-an-incredible-city-at-the-other-side-of-the-world
Press release - 08/08/2012 Apogenix: APG101 Exceeds Expectations with Controlled Phase II Clinical Trial The biopharmaceutical company Apogenix GmbH announced today that the phase II clinical proof of concept trial with APG101 as treatment of recurrent glioblastoma has met and exceeded expectations in the final analysis of the data. In this randomized controlled clinical study the patients were treated either with a combination of APG101 plus radiotherapy (APG101+RT group) or radiotherapy alone (RT group). The primary objective of the trial was to…https://www.gesundheitsindustrie-bw.de/en/article/press-release/apogenix-apg101-exceeds-expectations-with-controlled-phase-ii-clinical-trial
Press release - 26/05/2011 High Scientific Level at the Second International Workshop about Drug-Drug Interactions The organisation team of the Second International DDI drug-drug interactions Workshop has expressed great satisfaction with the course of the scientific meeting. Thus the DDI Workshop at Marbach Castle is on its way to become an established platform for the annual exchange between experts scientists members of the industry and regulatory bodies regarding DDI affairs.https://www.gesundheitsindustrie-bw.de/en/article/press-release/high-scientific-level-at-the-second-international-workshop-about-drug-drug-interactions
Article - 17/03/2014 Bacterial toxins manipulate proteins that serve as signalling switches in the host cell The enterobacterial species Photorhabdus asymbiotica und luminescens live in symbiosis with predatory nematodes that infest insect larvae and feed on their victims. The bacteria wait in the worms gut until their symbiotic partner has crept into the larvae then they are released and kill the insect with an ingenious toxin cocktail. Researchers in the team led by Professor Aktories and Dr. Thomas Jank recently discovered a mechanism of one of the…https://www.gesundheitsindustrie-bw.de/en/article/news/bacterial-toxins-manipulate-proteins-that-serve-as-signalling-switches-in-the-host-cell
Dossier - 30/08/2010 Disease prevention through better diagnostics “Classical treatment approaches are not the only way to ensure good health, rehabilitation and care. In fact, it is envisaged that more effective prevention will contribute to halting the development of diseases and maintaining good health. Prevention is designed to prevent health risks and diseases, make them less likely and delay their onset.” (Declaration of the German government; Official Records of Parliament 17/845, 26th February 2010) https://www.gesundheitsindustrie-bw.de/en/article/dossier/disease-prevention-through-better-diagnostics
Press release - 26/01/2011 ‘Complexes Matter’ in How Epigenetic Inhibitors Interact with Their Drug Targets Cellzome Scientists Publish First Chemoproteomic Characterization of HDAC Inhibitors in Nature Biotechnology. Results of the first ever chemoproteomic study of inhibition of HDAC Histone Deacetylase complexes opens up the potential for a new way of studying potency and selectivity for inhibitors of epigenetic drug targets such as HDACs. https://www.gesundheitsindustrie-bw.de/en/article/press-release/complexes-matter-in-how-epigenetic-inhibitors-interact-with-their-drug-targets
Article - 21/06/2008 Wanting children without risk In Germany one couple in ten is unable to conceive naturally. There are a number of different in vitro fertilisation methods available for those who wish to have children. However the potential risks to the child are still unknown.https://www.gesundheitsindustrie-bw.de/en/article/news/wanting-children-without-risk
Article - 02/05/2011 Production of high-density peptide arrays Frank Breitling and Alexander Nesterov-Müller from the Karlsruhe Institute of Technology KIT are working on the development of a second-generation peptide laser printer and a peptide chip printer based on computer chips. This development will enable the low-cost production of high-density peptide arrays consisting of up to one million peptides as well as opening up completely new areas of application.https://www.gesundheitsindustrie-bw.de/en/article/news/production-of-high-density-peptide-arrays
Vaccine development - 02/11/2015 A new vaccine could prevent influenza epidemics Influenza pandemics are dangerous and can claim many lives. Children and the elderly in particular run a high risk of developing influenza-related complications, because their immune system is often weakened by the virus. In Germany, annual vaccination against seasonal influenza has therefore been recommended for these target groups for quite a few years now. However, producing vaccines is costly and time-consuming. Researchers at the University…https://www.gesundheitsindustrie-bw.de/en/article/news/a-new-vaccine-could-prevent-influenza-epidemics
Dossier - 24/11/2009 Environmental medicine and biosensor technology Smog, chemicals in rivers, particular matter from copying machines in offices – human beings are exposed to many toxic influences. Environmental medical specialists are investigating the effect that these kinds of substances have at the same time as trying to find ways to reduce their influence on human health as much as possible. Molecular and cell biologists and even biotechnologists all have a key part to play in these efforts. On the one…https://www.gesundheitsindustrie-bw.de/en/article/dossier/environmental-medicine-and-biosensor-technology
Press release - 28/05/2009 CONCERT Medical Optics wins special CyberOne prize The company CONCERT Medical Optics was selected from more than 70 participants from all over Germany to receive a special CyberOne prize for the most innovative start-up concept namely a medical instrument called EndoTherapeuthoSkop. This instrument combines different technologies enabling the simultaneous detection and treatment of tumours meaning that patients only have to undergo one rather than several interventions.https://www.gesundheitsindustrie-bw.de/en/article/press-release/concert-medical-optics-wins-special-cyberone-prize
Article - 07/02/2008 New life sciences centre in Ulm The new Life Science Centre will house eleven interfaculty research groups dealing with aspects of tissue regeneration. The state of Baden-Württemberg and the University both expressed their high expectations for the centre at the official opening.https://www.gesundheitsindustrie-bw.de/en/article/news/new-life-sciences-centre-in-ulm
Press release - 16/10/2012 Merck Serono Launches € 1 Million Research Grant for Multiple Sclerosis Innovation Merck Serono, a division of Merck, Darmstadt, Germany, announced on 10th Oktober 2012 during the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) congress in Lyon, France, that the company has initiated a new global research award to improve understanding of multiple sclerosis for the ultimate benefit of patients.https://www.gesundheitsindustrie-bw.de/en/article/press-release/merck-serono-launches-1-million-research-grant-for-multiple-sclerosis-innovation
Article - 17/09/2012 Biochemisty and the assembly of ammonium machines Researchers who intend to build enzymes in the laboratory need detailed knowledge about the function of the respective enzymes. Using modern biochemistry methods researchers led by Prof. Dr. Oliver Einsle from the University of Freiburg have in the last few years clarified the atomic structure of a complex bacterial protein that converts atmospheric nitrogen into a form that can be readily used by other organisms. The researchers have recently…https://www.gesundheitsindustrie-bw.de/en/article/news/biochemisty-and-the-assembly-of-ammonium-machines
Article - 21/01/2013 Early warning signals of ageing in stem cells The large international project SyStemAge is specifically focused on the role of stem cells in ageing and age-related diseases. Coordinated by the European Molecular Biology Laboratory and the Heidelberg University Hospital the SyStemAge consortium seeks to identify the causes and molecular pathways associated with the processes of ageing on the stem-cell level as well as developing novel strategies for the early treatment of age-related…https://www.gesundheitsindustrie-bw.de/en/article/news/early-warning-signals-of-ageing-in-stem-cells
Article - 21/03/2016 Shock wave therapy gives hope to many men Although the approval of vasodilatory drugs made available an effective medicine for treating erectile dysfunction, not all men respond to this type of treatment. MTS Medical UG from Konstanz has developed a therapeutic device that means that these men can now get help too. What's more, the device has no adverse health effects.https://www.gesundheitsindustrie-bw.de/en/article/news/shock-wave-therapy-gives-hope-to-many-men
Article - 15/10/2012 Nobel Prize for the reprogramming of cells The Nobel Prize in Physiology or Medicine 2012 was awarded jointly to Sir John B. Gurdon and Shinya Yamanaka for the discovery that mature cells can be reprogrammed to become pluripotent, i.e. immature cells capable of developing into all tissues of the body. This finding is of revolutionary importance for the field of medicine.https://www.gesundheitsindustrie-bw.de/en/article/news/nobel-prize-for-the-reprogramming-of-cells
Article - 08/10/2012 A systems biology approach to understanding tumour growth Researchers at the Center Systems Biology in Stuttgart are developing multi-scale models of tumour growth with the aim of predicting how drugs spread and disperse in the tissue. The simulations can also take into account potential effects of pharmacological compounds and irradiation. The method will benefit researchers and clinicians by assisting them in their efforts to develop more efficient therapies. https://www.gesundheitsindustrie-bw.de/en/article/news/a-systems-biology-approach-to-understanding-tumour-growth
Press release - 30/01/2017 ChemCon celebrates 20th anniversary ChemCon GmbH, service provider for custom development and custom manufacturing of active pharmaceutical ingredients (APIs) and fine chemicals, based in the Innovationspark (innovations park) Freiburg, Germany, celebrates its 20th anniversary. On January 29 in 1997, Dr. Raphael Vogler (CEO) and Dr. Peter Gockel (CSO), both graduates from the Albert-Ludwigs-University Freiburg, signed the partnering contract to found ChemCon. Today they count 90…https://www.gesundheitsindustrie-bw.de/en/article/press-release/chemcon-celebrates-20th-anniversary
Press release - 26/03/2019 EUR 3 million in series A for the growth and development of Cytena GmbH The High-Tech Gründerfonds (HTGF) and two private investors are convinced of the importance of single-cell isolation for the production of biopharmaceuticals and for genetic analysis in research and diagnostics. EUR 3 million will be invested in the further development of the technology, the expansion of the sales organization and in opening up further applications for Cytena’s single-cell printers.https://www.gesundheitsindustrie-bw.de/en/article/press-release/eur-3-million-in-series-a-for-the-growth-and-development-of-cytena-gmbh
Article - 22/09/2009 Alwin Kienle: an eye for the whole picture Harvest time has now come for physicist Alwin Kienle. In the next year or two the results of his basic research will result in the establishment of an applied centre focusing on the determination of the optical characteristics of scattering media. The deputy director of the Ulm-based ILM hopes that the new optical competence centre will lead to attractive solutions for the pharmaceutical medical device and nutrition sectors.https://www.gesundheitsindustrie-bw.de/en/article/news/alwin-kienle-an-eye-for-the-whole-picture
Big Data - 13/03/2018 “More data does not automatically imply more knowledge“ In Germany, one of the big names in evidence-based medicine is Prof. Dr. rer. nat. Gerd Antes, co-director of Cochrane Germany. In the following interview, Antes talks about the hype surrounding big data, warns against false promises and reminds us about what is taken for granted. https://www.gesundheitsindustrie-bw.de/en/article/news/more-data-does-not-automatically-imply-more-knowledge